Biointelect and CR2O forge new strategic partnership to provide advanced end-to-end commercialisation solutions for the life science sector globally

Driving more efficient and accelerated results from pre-clinical trials to commercialisation of new therapies for Australian, European and U.S. firms.

The full innovation journey offering for Biointelect, a strategic life science consulting company, and CR2O, a leading contract research organisation, has reached new heights, with Australian, European and U.S. clients now able to tap into world-class strategic advice and full-service clinical trial capabilities following the announcement of Biointelect’s and CR2O’s new strategic partnership.

Biointelect and CR2O will work to provide our clients solutions across geographical boundaries and rapidly navigate an increasingly complex regulatory, access, policy and clinical landscape. Based in the Netherlands, CR2O is expanding Biointelect’s existing capability to include clinical trial capabilities across the European Union and Australia. The partnership will give CR2O access to Biointelect’s strategic product development consultancy and commercialisation capabilities.

The transformational move puts Biointelect and CR2O at the forefront for providing world-class innovative end-to-end commercialisation solutions to streamline project work across every phase of the development cycle.

Biointelect CEO Leah Goodman said ultimately this collaborative partnership will mean strengthened confidence for clients in reaching their goals and an enhanced customer experience with a focus on performance.

“We are delighted that our partnership with CR2O enhances the full value Biointelect brings to our clients, completing our partnership capability from early research right through to commercialisation.”

“The alliance with CR2O will generate even greater returns to clients across the full innovation journey via a consolidated service offer with a trusted partner.”

“Biointelect’s reputation for quality is a common value with CR2O, and we are confident that together this global expansion will continue to enable our collaboration with Life science partners in enhancing the ecosystem and bringing innovation to patients,” Goodman added.

Trusted connections

The strategic partnership harnesses the deep insights, ground support and local presence of both CR2O and Biointelect for Australian, European and U.S. clients across the pharmaceutical and biotechnology industries.

Core to the advancement strategy is an understanding of the macroeconomic and geopolitical tensions that often impact the sector, to deliver fit-for-purpose clinical development solutions that de-risk the pathway to patient care settings.

CR2O CEO Hadil Es-Sbai believes the partnership with Biointelect will strengthen strategic capabilities by leveraging established relationships with stakeholders to provide advanced end-to-end commercialisation solutions for clients.

“We are very pleased to strengthen our collaboration with Biointelect by leveraging their world-class strategic planning and commercialisation capabilities for the benefit of our pharmaceutical and biotechnology clients. Together we offer integrated, fit-for-purpose clinical development solutions that de-risk the complex journey from bench to bedside,” said Es Sbai.


Performance driven

The new partnership has ushered in a wave of enquiries from universities, government, biotechnology and pharmaceutical companies seeking a wholistic, one-stop-shop for tailored solutions across the full innovation journey. With a synergy in values underpinning the partnership’s success, both will leverage their proven track records to continue a trajectory of bringing life science innovations to market.

“At the end of the day, our aim is to deliver outstanding results for our clients through an efficient and accelerated approach with a focus on reliability and credibility. Our partnership with CR2O enhances our ability to provide value to our now shared clients.” Goodman said.



Australia: Biointelect CEO Leah Goodman

With a career spanning executive leadership roles at Bristol-Myers Squibb, Merck Healthcare, and Sanofi, Leah has excelled in diverse therapeutic areas, from immunooncology to primary care.

She has significant experience successfully leading Multinational company business transformation and growth in Australia and across Asia including South East Asia, Korea, and Japan.

In November 2023, Leah commenced as Chief Executive Officer at Biointelect. Drawing on her extensive leadership background, she has embarked on successfully engaging the company to a this new strategic vision and long term success.

Related Posts